The OPERA study, conducted by ADSCC, aims to evaluate the safety and efficacy of Extracorporeal Photopheresis (ECP) as a potential treatment for type 1 diabetes mellitus (T1DM).
To be eligible for the study, patients must meet specific criteria, including a confirmed T1DM diagnosis within the first 3 years of onset, use of multiple dose injection therapy, and certain blood parameter requirements. The study is open to individuals aged 18 to 50 who are willing to participate in all tests, visits, and ECP procedures outlined in the informed consent.
The study involves two treatment groups: Group A receives ECP at regular intensity in addition to T1DM standard care, while Group B receives ECP at an accelerated intensity along with standard care. ECP, a procedure with a history of use in various conditions, involves drawing blood, separating white blood cells, combining them with a photoactive drug, and reinfusing them into the patient.
The ECP procedure for each group follows a specific schedule over 24 weeks. Potential risks associated with ECP include common symptoms, bleeding, bruising, pain, infection at the needle sites, citrate-related reactions, allergic reactions, blood-related issues, and rare complications like air embolism or retinal damage.
The primary objective of the study is to assess safety, with a co-primary objective of improving clinical status within 24 weeks post-ECP treatment. Patients will undergo various examinations, including clinical evaluations and specialized laboratory investigations, to assess the effects of the treatment. Additional information about the OPERA Study is available on ClinicalTrials.gov (NCT05413005) or through the provided contact details.
ADSCC’s “SHABABAK” Anti-Aging Program is a meticulously designed personalized health plan to prevent age-related diseases and enhance overall well-being. Integrating IV therapy, oral supplements, and tailored nutrition, this program focuses on cellular health and vitality.
Our approach goes beyond surface-level concerns by addressing aging at its core, emphasizing disease prevention and promoting internal health. The unique combination of IV therapy, oral supplements, and personalized nutrition supports immune function, enhances cellular repair, and boosts energy levels.
Tailored to individual health needs, this personalized strategy maximizes program benefits. Advanced ingredients like resveratrol, NAD infusion, and NAD booster supplements further contribute to the program’s rejuvenating properties.
The program spans 3 months, including a focused 4-week IV infusion phase and a 3-month dietary intervention with orally delivered supplements. While individual outcomes may vary, many participants report increased energy and vitality within the initial weeks, with ongoing improvements observed over time with consistent adherence.
Ideal for anyone proactive about health management, the “SHABABAK” Anti-Aging Program at ADSCC is designed to prevent age-related diseases, enhance vitality, and improve overall well-being.
If you are interested in taking part in our “SHABABAK” Anti-Aging Program, please contact 800 140 to schedule an appointment with our consultant physician, who will assess your eligibility for the program.
Mahdar Qutouf Street, Rowdhat, Abu Dhabi, UAE
Near Al Rawafed Pvt. School - Mhanna St - Khalifa City - SE44 - Abu Dhabi, UAE